Get the Stockscreener App
16.05
0.12%
-0.02
After Hours:
16.05
Aurinia Pharmaceuticals Inc stock is traded at $16.05, with a volume of 854.05K.
It is down -0.12% in the last 24 hours and up +15.05% over the past month.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
See More
Previous Close:
$16.07
Open:
$16.09
24h Volume:
854.05K
Relative Volume:
0.83
Market Cap:
$2.13B
Revenue:
$283.06M
Net Income/Loss:
$287.20M
P/E Ratio:
7.7271
EPS:
2.0771
Net Cash Flow:
$135.69M
1W Performance:
+1.01%
1M Performance:
+15.05%
6M Performance:
+39.93%
1Y Performance:
+107.10%
1-Day Range:
$15.77
$16.12
1-Week Range:
$15.56
$16.54
52-Week Range:
$7.285
$16.54
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Name
Aurinia Pharmaceuticals Inc
Sector
Industry
Phone
250-744-2487
Address
#140, 14315 - 118 AVENUE, EDMONTON, BC
Compare AUPH vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
16.05 | 2.14B | 283.06M | 287.20M | 135.69M | 2.0771 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Nov-07-25 | Upgrade | Jefferies | Hold → Buy |
| Nov-05-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-30-25 | Resumed | H.C. Wainwright | Buy |
| Nov-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
| May-05-22 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-28-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-25-21 | Reiterated | H.C. Wainwright | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| May-05-20 | Initiated | Cowen | Outperform |
| Jan-10-20 | Initiated | Jefferies | Buy |
| Dec-16-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-16-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Feb-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-30-17 | Reiterated | H.C. Wainwright | Buy |
| May-18-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-11-17 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-22-17 | Reiterated | FBR & Co. | Outperform |
| Dec-30-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-17-16 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-16 | Initiated | H.C. Wainwright | Buy |
| May-08-15 | Initiated | MLV & Co | Buy |
View All
Aurinia Pharmaceuticals Inc Stock (AUPH) Latest News
How activist investor Kevin Tang finally landed the Bay Area company that got away from him - The Business Journals
Trading Systems Reacting to (AUPH) Volatility - Stock Traders Daily
Aurinia to Acquire Kezar (NASDAQ: KZR) for $6.955 Cash plus CVR - Stock Titan
Ideas Watch: Is Aurinia Pharmaceuticals Inc gaining market sharePortfolio Gains Report & Fast Gaining Stock Reports - baoquankhu1.vn
Guidance Update: Does Aurinia Pharmaceuticals Inc stock have upside surprise potentialBond Market & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Aurinia to buy Kezar (KZR) for $6.955/Share plus CVR (7.39M shares) - Stock Titan
AUPH Stock Price, Quote & Chart | AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) - ChartMill
Dow Update: Whats the profit margin of Aurinia Pharmaceuticals Inc2026 Summary & Detailed Earnings Play Alerts - baoquankhu1.vn
Proxy StatementNotice of Shareholders Meeting (preliminary) (pre 14a) - ADVFN
AUPHAurinia Announces Results of Annual General Meeting - ADVFN
RSI Check: Can Aurinia Pharmaceuticals Inc grow without external fundingDip Buying & Short-Term High Return Ideas - baoquankhu1.vn
Downgrade Watch: Why is Aurinia Pharmaceuticals Inc stock going up2026 Geopolitical Influence & Weekly Setup with High ROI Potential - baoquankhu1.vn
Kezar Life Sciences shares surge after Aurinia announces acquisition - MSN
Stock Analysis: Will Aurinia Pharmaceuticals Inc benefit from government policyEarnings Risk Report & Risk Managed Trade Strategies - baoquankhu1.vn
7MM Systemic Lupus Erythematosus and Lupus Nephritis Drug Market Analysis & Forecast 2024-2034: Future SLE and LN Players Competition, High Unmet Need for Steroid-sparing Treatments - GlobeNewswire Inc.
AUPH News | AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) - ChartMill
Aurinia Pharmaceuticals Acquisition Of Kezar Reshapes Autoimmune Growth And Risks - Sahm
AUPH Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
AUPH Technical Analysis & Stock Price Forecast - Intellectia AI
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q3 2025 Earnings Call Transcript - MSN
Moving Averages: Is Aurinia Pharmaceuticals Inc part of any major index2026 Retail Activity & Safe Entry Momentum Tips - baoquankhu1.vn
Aurinia Pharmaceuticals acquiring Kezar Life Sciences - MSN
A Look At Aurinia Pharmaceuticals (AUPH) Valuation After Its Recent Leadership Overhaul - Sahm
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.96 Per Share Plus Contingent Value Rights in 2026 Merger Deal - Minichart
Why Aurinia Pharmaceuticals stock is surging Monday morning - MSN
Aurinia Pharmaceuticals to Acquire Kezar, Expanding Autoimmune Pipeline - TipRanks
Aurinia to Acquire Kezar via $6.955-Per-Share Cash Tender Plus CVR - TradingView — Track All Markets
Aurinia (NASDAQ: AUPH) to acquire Kezar with $6.955 per share cash and CVRs - Stock Titan
Aurinia to acquire Kezar (NASDAQ: KZR) for $6.955 cash plus CVR - Stock Titan
How Aurinia Pharmaceuticals Inc (AUPH) Affects Rotational Strategy Timing - Stock Traders Daily
Aurinia Pharmaceuticals Inc. (AUP.TO) Competitors - Meyka
Aurinia Pharmaceuticals (AUPH) COO Ryan Cole becomes SEC Form 3 insider - Stock Titan
Aurinia Pharmaceuticals (AUPH) CFO Michael Hearne becomes reporting insider with Form 3 - Stock Titan
Major Kezar (KZR) shareholder signs merger support pact and drops bid - Stock Titan
JPMorgan Chase & Co. Grows Stock Holdings in Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
Aurinia Pharmaceuticals: $6.955 Per Share Acquisition Of Kezar Life Sciences To Expand Autoimmune Pipeline - Pulse 2.0
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right - Zenopa
Aurinia to acquire Kezar Life Sciences - The Pharma Letter
EBIT per share of Aurinia Pharmaceuticals Inc. – LSE:0UJF - TradingView
KZR Acquisition by Aurinia Pharmaceuticals Valued at $6.955 per Share - GuruFocus
Aurinia to Acquire Kezar Life Sciences (KZR) in Strategic Deal - GuruFocus
After failed takeover bid, activist investor finds new way to buy out Bay Area company - The Business Journals
Aurinia Pharma U.S., Inc. agreed to acquire Kezar Life Sciences, Inc. for $51 million. - marketscreener.com
Aurinia to acquire Kezar Life Sciences for $6.955 per share By Investing.com - Investing.com South Africa
Aurinia Pharmaceuticals Acquires Kezar Life Sciences - Contract Pharma
Aurinia to Buy Kezar Life Sciences in Cash-and-CVR Autoimmune Deal - TipRanks
Kezar Life Sciences stock jumps on Aurinia acquisition deal By Investing.com - Investing.com Australia
Aurinia Pharmaceuticals Inc Stock (AUPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):